Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438586 | 0.81 | MAPT (0.48) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL380136 | 0.81 | MAPT (0.48) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL6347021 | 0.81 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL7530553 | 0.78 | MAPT (0.46) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL1150739 | 0.78 | XDH (0.47) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL4372319 | 0.77 | MAPT (0.44) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL5173509 | 0.77 | MAPT (0.44) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL9386889 | 0.77 | MAPT (0.44) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL3423321 | 0.77 | MAPT (0.44) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL6233162 | 0.75 | XDH (0.51) | MAPTADORA2BXDHALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| EP-2233472-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2014-01-15 | — | — | EP | disclosed |
| US-8614319-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-12-24 | — | — | US | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| EP-2010505-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007110868-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | MAPT 3849/4885ADORA2B 611/4885GDA 774/4885 |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | MAPT 4045/4885ADORA2B 364/4885GDA 749/4885 |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | MAPT 3849/4885ADORA2B 611/4885GDA 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.